Subject Index

ABCB1
  clopidogrel and polymorphism effects 107, 108
  ticagrelor metabolism individual differences 73
Abciximab
  non-ST-elevation acute coronary syndrome management 12
  ST-elevation myocardial infarction management 10
Acute coronary syndromes (ACS), see also specific conditions
  antiplatelet therapy impact overview, see also specific drugs
  non-ST-elevation syndromes 10–12
  overview 5–7
  ST-elevation myocardial infarction 7–10
  platelet activation 6, 7
  protease-activated receptor-1 inhibitor therapy, see Protease-activated receptor-1 inhibitors
Apixaban, atrial fibrillation management 16
Aspirin (ASA)
  acute coronary syndrome management
    acute myocardial infarction 23
    non-ST-elevation acute coronary syndrome management 11
    primary prevention studies 25
    secondary prevention studies 23–25
  ST-elevation myocardial infarction management 7, 8
  unstable angina 23
  bleeding complications 131, 132
  dosage 21, 22
  historical perspective 2–4
  mechanism of action 21
  pharmacokinetics 21
  resistance 22
  side effects 22
  stent thrombosis inhibition 118
  stroke prevention studies
    atrial fibrillation studies 15, 16, 25, 149, 151, 156, 157
    primary prevention 142, 143
    secondary prevention 144, 145
  triple therapy for percutaneous coronary intervention use in atrial fibrillation 158–160
Atrial fibrillation (AF), see also Stroke
  apixaban therapy 16
  aspirin studies 15, 16, 25, 156, 157
  bleeding risk assessment in management 157, 158, 162
  clopidogrel therapy 16, 17, 25
  CYP2C19 polymorphism impact on management 107
  dabigatran therapy 15, 16, 161
  epidemiology 12
  indobufen therapy 17
  percutaneous coronary intervention and warfarin use 158–160
  rivaroxaban therapy 16
  stroke
    pathophysiology 12, 13
    prevention
      clopidogrel plus aspirin studies 149
      overview 145, 146
      primary prevention 146
      prospects 161, 162
secondary prevention 146–148
warfarin 15, 16, 146, 148
risk assessment 13, 14, 155–158
triflusal therapy 17

Bivalirudin, renal function and dose adjustment 136

Bleeding complications
aspirin 131, 132
cangrelor 135
clinical registry definitions 128
clinical trial definitions 126–128
clopidogrel 132–134
glycoprotein IIb/IIIa inhibitors 135
mortality mechanisms 129–131
outcome studies 128, 129
prasugrel 134
protease-activated receptor-1 inhibitors 136
risk assessment in atrial fibrillation management 157, 158, 162
risk reduction 136, 137
ticagrelor 71, 72, 134
warfarin 146

Cangrelor
bleeding complications 135
stroke prevention studies 149, 150
CHADS2, stroke risk assessment in atrial fibrillation 13, 14, 155–158

Clopidogrel
ABCB1 polymorphism effects 107, 108
acute coronary syndrome management non-ST-elevation acute coronary syndrome management 11, 32 percutaneous coronary intervention studies 32
ST-elevation myocardial infarction management 8, 9, 33
atrial fibrillation management 16, 17, 25
bleeding complications 132–134
combination antithrombotic therapy 34, 35
CYP2C19 polymorphism studies candidate gene studies 104
genome-wide association studies 103, 104
loading dose 33, 34
metabolism 101, 102
PON1 polymorphism effects 10
prehospital administration 34
stent thrombosis inhibition 119
stroke prevention studies atrial fibrillation studies 149

primary prevention 143
secondary prevention 144, 145
surgery considerations 35

Coronary artery bypass grafting (CABG)
aspirin studies 24, 25
prasugrel studies 54

CYP2C19
atrial fibrillation treatment and polymorphism impact 107
cardiovascular outcomes of purinergic receptor antagonist therapy by genotype clinical trials 104–106
meta-analysis 106
clopidogrel metabolism studies candidate gene studies 104
clinical decision making 109, 110
combination therapy prasugrel 108
ticagrelor 108, 109
genome-wide association studies 103, 104
high-dose therapy 109
loss-of-function alleles 102, 103
metabolic phenotype prediction from variants 103
ticagrelor metabolism individual differences 73

Dabigatran, atrial fibrillation management 15, 16, 161
Diabetes, prasugrel studies in coronary heart disease patients 52

Diprydamol
antithrombotic activity overview 79, 80
plasma concentration importance 80, 81
thrombin formation inhibition 82, 83
innate inflammation inhibition 84
pleiotropic effects in tissue protection 81, 82, 84, 85
restenosis prevention 83, 84
stroke prevention studies 144, 145

Eichengrün, Arthur 3, 4

Enoxaparin, renal function and dose adjustment 136

Elinogrel, stroke prevention studies 149, 150

Restenosis prevention studies 144, 145

Eileath, William 5, 6
Eptifibatide
- non-ST-elevation acute coronary syndrome management 12
- renal function and dose adjustment 136

Exoxaparin, renal function and dose adjustment 136

Gerhardt, Charles Fredric 3

Glycoprotein IIb/IIIa inhibitors, see also specific drugs
- bleeding complications 135
- stent thrombosis prevention 119

Indobufen, atrial fibrillation management 17

Link, Karl Paul Gerhardt 1, 2

Monocyte chemoattractant protein-1 (MCP-1), dipyridamole inhibition 84

Non-ST-elevation acute coronary syndrome
- antiplatelet therapy overview 10–12
- clopidogrel management 11, 32
- prasugrel management 11

Paraoxonase-1 (PON1), clopidogrel metabolism and polymorphism effects 108

Percutaneous coronary intervention (PCI)
- aspirin studies 24
- clopidogrel studies 32
- dipyridamole and restenosis prevention 83, 84
- prasugrel studies 46–50
- stent thrombosis
  - antiplatelet agents in prevention
    - aspirin 118
    - clopidogrel 119
    - glycoprotein IIb/IIIa inhibitors 119
    - prasugrel 119
    - recommendations 120
    - ticagrelor 119
    - ticlopidine 119
  - definitions 115, 116
  - history of study 114, 115
  - incidence 115
  - outcomes 115, 116
  - pathophysiology 116–118
  - stent design impact 119, 121
- vorapaxar studies 93
- warfarin use in atrial fibrillation 158–160

P-glycoprotein, see ABCB1

Phosphodiesterase 5 (PDE5), dipyridamole inhibition 82

Platelet Inhibition and Patient Outcomes trial (PLATO)
- baseline characteristics and randomized treatment 67
- efficacy 67, 68
- safety outcomes
  - arrhythmia 72
  - bleeding 71, 72
  - dyspnea 72
  - renal function 72, 73
  - study design 66, 67
  - subanalysis 69, 70

Prasugrel
- acute coronary syndrome management
  - clinical trials
    - completed trials 43–45
    - ongoing trials 55–58
  - coronary artery bypass grafting studies 54
  - diabetic patients 52
  - early and late event impact 49
  - high-risk patients 52–54
  - non-ST-elevation acute coronary syndrome management 11
  - percutaneous coronary intervention studies 46–50
  - recurrence impact 50, 51
  - ST-elevation myocardial infarction management 9, 51, 52
  - bleeding complications 134
  - cost-effectiveness 54, 55
  - CYP2C19 polymorphism and clopidogrel combination therapy 108
  - metabolism 101, 102
  - pharmacology and drug interactions 40–42, 45
  - stent thrombosis inhibition 119
  - stroke prevention studies 149

Protease-activated receptor-1 (PAR-1), inhibitors atopaxar
- acute coronary syndrome trials 95–97
- metabolism 91
- platelet inhibition activity 94, 95
- structure 91
- bleeding complications 136
- mechanism of action 90, 94
- prospects 97, 98
- rationale for development 88, 89
vorapaxar
  acute coronary syndrome trials
    Phase II 92–94
    Phase III 94
  metabolism 91, 92
  structure 91

Rivaroxaban, atrial fibrillation management 16

Schofield, Francis William 1, 2
ST-elevation myocardial infarction (STEMI)
  abciximab therapy 10
  antiplatelet therapy overview 7–10
  aspirin therapy
    overview 7, 8, 23
    primary prevention studies 25
    secondary prevention studies 23–25
  clopidogrel therapy 8, 9, 33
  prasugrel therapy 9, 51, 52
  ticagrelor therapy 9
  ticlopidine therapy 8, 9
Stenting, see Percutaneous coronary intervention
Stroke, see also Atrial fibrillation
  epidemiology 141, 142
  primary prevention
    aspirin 142, 143
    clopidogrel 143
  prospects for prevention 149–151
  secondary prevention
    antiplatelets versus anticoagulants 145
    aspirin 144, 145
    clopidogrel 144, 145
    combination therapy 144, 145
    dipyridamole 144, 145

Ticagrelor
  acute coronary syndrome management
    non-ST-elevation acute coronary syndrome management 12
    ONSET/OFFSET study 73, 74
    RESPOND study 73, 74
    ST-elevation myocardial infarction management 9
  bleeding complications 71, 72, 134
  cost-effectiveness 74, 75
  CYP2C19 polymorphism and clopidogrel combination therapy 108, 109
  drug interactions 74
  mechanism of action 64, 65
  metabolism and individual differences 73

Platelet Inhibition and Patient Outcomes
  trial
    baseline characteristics and randomized treatment 67
    efficacy 67, 68
    safety outcomes
      arrhythmia 72
      bleeding 71, 72
      dyspnea 72
      renal function 72, 73
    study design 66, 67
    subanalysis 69, 70
    stent thrombosis inhibition 119
    stroke prevention studies 149, 150

Ticlopidine
  ST-elevation myocardial infarction management 8, 9
  stent thrombosis inhibition 119

Tirofiban, renal function and dose adjustment 136

Triflusal, atrial fibrillation management 17

Unstable angina, see Acute coronary syndromes

Vorapaxar
  acute coronary syndrome trials
    Phase II 92–94
    Phase III 94
  metabolism 91, 92
  structure 91

Warfarin
  bleeding complications 146
  historical perspective 1, 2
  percutaneous coronary intervention use in atrial fibrillation 158–160
  stroke prevention in atrial fibrillation 15, 16, 146, 148